Loncar Cancer Immunotherapy ETF News

Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.

These sectors topped last week and beat the broader market in a sweeping move.

These sectors topped last week and beat the broader market in a sweeping move.

Gainers: DB Crude Oil -2X ETN Powershares (NYSEARCA:DTO) +81.4%.BMO Rex Microsectors Fang Index 3X Leveraged Ex (NYSEARCA:FNGU) +35.0%.Direxion S&P Biotech Bull 3X (NYSEARCA:LABU) +30.2%.Ultrashor

Like punk rock, alpha is very much alive.

Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.

Despite the coronavirus concerns that have hit commodity markets and, in turn, energy and basic materials stocks, U.S. tech stocks have posted strong returns to

US healthcare is always a political hot potato, and volatility is expected to rise as the November elections approach. The US healthcare sector traded at a pric

Biotech ETFs are among the most popular investment vehicles. Here are some reasons for why they're worth considering.

The volatile segment struggled to catch a break, then rallied, and now sits in the limelight of a virus outbreak.

EQRx's plan is apparently to come up with new competing pharmaceuticals in existing categories and sell them for lower prices than the patented ones. Insurance

We highlight five biotech ETFs and stocks that are leading the market in Q4.

Can biotech ETFs repeat its success story of 2019 in the election year of 2020?

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

Increasing M&A; deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.